When a drug meant for sick lungs quietly started making people seem younger on the inside, a team of scientists took notice. The medicine is called rentosertib, developed by the company Insilico Medicine in 2025 to treat idiopathic pulmonary fibrosis (IPF), a severe lung disease that strikes mostly older adults. Its job was to slow down the scar tissue building up in patients' lungs. But the scientists behind it suspected it might be doing something far bigger: slowing down aging itself.
Here is why that idea is not as strange as it sounds. Over the past few decades, researchers have found a huge overlap between the biology of aging and the biology of disease. Many of the same processes that make us age also make us sick. That means a drug built to treat an age-related disease can sometimes reach into the very pathways that drive aging. Rentosertib does this by blocking a protein called TNIK, which plays a role in both lung scarring and basic hallmarks of biological aging.
To test the idea in humans, researchers at Insilico Medicine turned to blood samples from a 12-week clinical trial of 42 IPF patients. The patients were split into four groups: a placebo group, and groups taking 30 mg once daily, 30 mg twice daily, or 60 mg once daily of rentosertib. Blood was drawn at four points — the start, then weeks 2, 4, and 12. Using a high-throughput platform, the team measured 2,841 circulating proteins in every sample.
Then came the clever part. They ran the data through six different "proteomic clocks" — tools that estimate a person's biological age by measuring thousands of proteins floating in the blood. Unlike a calendar age, a biological age tells you how your body is actually holding up. All six clocks pointed the same way: patients who got rentosertib showed a younger biological age than those in the placebo group. The effect stood out most clearly after four weeks in the group taking 30 mg twice daily.
The researchers went even further. They compared the patient samples with aging data from 55,319 UK Biobank participants. Among the 2,832 proteins measured in both datasets, the ones touched by rentosertib were 1.74 times more likely to be linked to aging than you'd expect by chance. That hinted the drug's effects went beyond its antifibrotic action — it seemed to be nudging the aging process itself.
This matters because most drug trials measure one disease outcome and never ask whether the treatment touches broader aging. Protemics clocks offer a way to see that. Earlier "epigenetic" clocks, which read age-related changes in DNA, often gave inconsistent results. Proteomic clocks read blood proteins instead, making them quicker to respond to changes like medication.
None of this means rentosertib is a fountain of youth yet. But for the first time, a lung drug has been shown to visibly shift biological age in humans, measured by six independent clocks in agreement. If drugs can be built to treat disease and slow aging at once, the future of medicine might get a lot more hopeful — one protein at a time.